Resumo

HUNG, Allen et al. Expression of androgen receptors in patients with triple-negative subtype breast carcinoma. Invest. clín [online]. 2024, vol.65, n.1, pp.59-69.  Epub 09-Mar-2024. ISSN 0535-5133.  https://doi.org/10.54817/ic.v65n1a06.

Breast carcinoma of the triple-negative subtype (TNBC) does not express estrogen, progesterone or human epidermal growth factor receptor 2 (HER2) receptors. A subclassification of TNBC has been proposed into four subgroups, one of which is the luminal androgen receptor. The objective of this work was to determine the expression of the androgen receptor (AR) in women with TNBC, diagnosed by immunohistochemistry, at the Hospital Metropolitano del Norte, Valencia, Venezuela. The sample consisted of 191 patients who met the inclusion criteria. The mean age of the patients at the time of diagnosis was 54.91 years. Histologically, the majority of the tumors were moderately differentiated or undifferentiated. The percentage of AR expression was 22% (42 of 191). In the association between AR expression and the Ki-67 proliferative index, a greater number of AR positive cases was observed in tumors with Ki-67 expression of less than 40%. The AR positivity found in this study represents an intermediate frequency in relation to other investigations. No statistically significant differences were found with the age of the patients and histological grade of the tumors, while the Ki-67 proliferative index was lower for AR+ tumors, compared to TNBC in general.

Palavras-chave : breast carcinoma; triple negative; androgen receptor; immunohistochemistry.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )